Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT02492711

Public ClinicalTrials.gov record NCT02492711. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.

Study identification

NCT ID
NCT02492711
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
MacroGenics
Industry
Enrollment
624 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 23, 2015
Primary completion
Aug 10, 2021
Completion
Jun 13, 2022
Last update posted
Mar 16, 2025

2015 – 2022

United States locations

U.S. sites
62
U.S. states
28
U.S. cities
60
Facility City State ZIP Site status
Ironwood Cancer & Research Center Chandler Arizona 85224
Banner MD Anderson Cancer Center Gilbert Arizona 85234
Western Regional Medical Center, Inc. Goodyear Arizona 85338
East Valley Hematology And Oncology Burbank California 91505
UCLA Hematology Oncology Santa Monica Los Angeles California 90095
UC Davis Comprehensive Cancer Center Sacramento California 95817
Sharp Memorial Hospital San Diego California 92123
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California 94115
Kaiser Permenente Medical Center Vallejo California 94589
Poudre Valley Health Care, Inc. Fort Collins Colorado 80528
MedStar Washington Hospital Center Washington D.C. District of Columbia 20010
Florida Cancer Specialists Fort Myers Florida 33916
Memorial Cancer Institute at Memorial Regional Hospital Hollywood Florida 33021
Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140
Florida Cancer Specialists New Port Richey Florida 34655
Orlndo Health Cancer Center Orlando Florida 32806
Hem-Onc Associates Port Saint Lucie Florida 34952
Palm Beach Cancer Center West Palm Beach Florida 33401
Piedmont Cancer Institute, P.C. Atlanta Georgia 30318
Northwest Georgia Oncology Centers, PC Marietta Georgia 30060
CTCA - Southeastern Regional Medical Center Newnan Georgia 30265
Kaiser Permanente Hawaii Moanalua Medical Center Honolulu Hawaii 96819
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
Rush University Medical Center Chicago Illinois 60612
Carle Cancer Center Urbana Illinois 61801
CTCA - Midwestern Regional Medical Center Zion Illinois 60099
Indiana University Health Goshen Center for Cancer Care Goshen Indiana 46526
ARH Cancer Clinic Hazard Kentucky 41701
St. Joseph's Hospital Lexington Kentucky 40504
Touro Infirmary Hospital New Orleans Louisiana 70115
New England Cancer Specialists Scarborough Maine 04074
Mercy Medical Center Baltimore Maryland 21202
Tufts-NEMC Cancer Center Boston Massachusetts 02111
Forrest General Hospital Hattiesburg Mississippi 39401
Saint Luke's Cancer Specialists Kansas City Missouri 64111
Mercy Hospital Saint Louis St Louis Missouri 63141
Dartmouth-Hitchcock - Norris C Lebanon New Hampshire 03756
New Jersey Hematology Oncology Associates Brick New Jersey 08724
Hackensack University Medical Center Hackensack New Jersey 07601
Saint Barnabas Medical Center - The Cancer Center Livingston New Jersey 07039
New Mexico Cancer Care Alliance (NMCCA) Albuquerque New Mexico 87106
Queens Hospital Center Jamaica New York 11432
ProHEALTH CARE Associates, LLP Lake Success New York 11042
New York University Clinical Cancer Center New York New York 10016
Wake Forest University Baptist Medical Center (WFUBMC) Winston-Salem North Carolina 27157
Mercy Physicians Of Oklahoma Oklahoma City Oklahoma 73120
Pinnacle Health Cancer Institute Harrisburg Pennsylvania 17109
Monongahela Valley Hospital Monongahela Pennsylvania 15063
CTCA - Eastern Regional Medical Center, Inc. Philadelphia Pennsylvania 19124
Guthrie Medical Group, PC Sayre Pennsylvania 18840
Tennessee Oncology, PLLC Chattanooga Tennessee 37404
The Sarah Cannon Research Institute Nashville Tennessee 37203
Austin Cancer Center Austin Texas 78758
University of Texas Southwestern Medical Center Dallas Texas 75390
The Center for Cancer and Blood Disorders Fort Worth Texas 76104
Utah Cancer Specialists Salt Lake City Utah 84106
University of Virginia Cancer Center Charlottesville Virginia 22908
Inova Schar Cancer Institute Fairfax Virginia 22031
Fort Belvoir Community Hospital Fort Belvoir Virginia 22060
Swedish Cancer Institute/ Swedish Health Services Seattle Washington 98104
University of Washington/ Seattle Cancer Care Alliance Seattle Washington 98109
Cancer Care Northwest, PS Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02492711, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02492711 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →